ADCs in Gynecologic Cancer Care: Enhancing the Patient’s Treatment Journey Through Optimal Adverse Event Management

Please visit answersincme.com/MSM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ritu Salani, MD; and Courtney Arn, CNP. In this activity, experts in gynecological oncology discuss antibody-drug conjugates (ADCs) in ovarian, cervical, and endometrial cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for using ADCs in previously treated patients with gynecologic cancers; Assess the safety and tolerability evidence for approved ADC therapies in gynecologic cancers; Formulate management strategies for adverse events associated with ADC treatment of ovarian, cervical, and endometrial cancers; and Outline patient-centered approaches to facilitate adherence with ADC therapy.

Please visit answersincme.com/FSP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jay N. Yepuri, MD, MS, FACG, FTSGE. In this activity, an expert in gastroenterology discusses molecular prognostics tests that predict the risk of progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC). Upon completion of this activity, participants should be better able to: Describe the limitations of traditional approaches to predicting risk of progression to EAC for patients with BE; Review the evolving role of advanced molecular prognostic tests in assessing risk of progression to EAC in patients with BE; and Outline multidisciplinary strategies to integrate advanced molecular prognostic tests into the management of patients with BE.

Please visit answersincme.com/WAY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth O'Donnell, MD. In this activity, an expert in multi-cancer early detection (MCED) discusses strategies to apply MCED testing into everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the benefits and risks of MCED testing; and Outline patient-centered strategies to appropriately incorporate MCED testing into the primary care setting.

Please visit answersincme.com/BVK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jesus E. Pina-Garza, MD. In this activity, an expert in epilepsy discusses recognizing seizure emergencies, selecting appropriate rescue treatments and routes of administration, and developing individualized seizure action plans. Upon completion of this activity, participants should be better able to: Define seizure emergencies based on expert consensus to support accurate treatment decisions; Evaluate approved therapeutic approaches for the management of seizure clusters in the home/community setting; and Identify strategies to support the timely use of acute seizure medications through patient-centered seizure action plans.

Please visit answersincme.com/860/cvdprostate-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Cookson, MD; Alicia Morgans, MD, MPH; and Avirup Guha, MD, MBBS, MPH, FAHA, FACC, FESC, FICOS. In this activity, experts in prostate cancer discuss cardiovascular risk in patients receiving androgen-deprivation therapy (ADT). Upon completion of this activity, participants should be better able to: Evaluate the impacts of prostate cancer and ADT on cardiovascular risk; Translate the latest research for cardiovascular management of patients on ADT to clinical practice; and Design personalized treatment approaches to optimize ADT across treatment settings.

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Please visit answersincme.com/TZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James E. Galvin, MD, MPH. In this activity, an expert in Alzheimer’s disease (AD) discusses treatment of early AD with anti-amyloid therapies. Upon completion of this activity, participants should be better able to: Review the latest advances in anti-amyloid therapies for the treatment of early Alzheimer’s disease (AD; Assess the current evidence on anti-amyloid therapies, including maintenance strategies, for the treatment of early AD; and Outline strategies to integrate the latest advances in anti-amyloid therapies to practice to improve long-term outcomes for patients with early AD.

Please visit answersincme.com/BHT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara Stafford, MDCM, FRCPC and Gihane Zarifa, MD, CCFP, FCFP, MSc. In this activity, experts in family medicine and endocrinology discuss the role of oral glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) in personalized type 2 diabetes (T2D) management. Upon completion of this activity, participants should be better able to: Discuss individualized, guideline-informed management strategies for T2D that address glycemic control, weight, and patient-specific factors; Differentiate key pharmacologic, administration, and tolerability characteristics of oral GLP-1 RAs to support patient counseling in T2D; and Interpret clinical evidence for approved and emerging oral GLP-1 RAs to inform their potential role in addressing gaps in T2D management.

Please visit answersincme.com/RVH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vivien Brown, MDCM, CCFP, FCFP, MSCP. In this activity, an expert in menopause management in primary care discusses identification and treatment of menopause-related vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Integrate communication about menopause and VMS into routine patient encounters; Review treatment options for moderate to severe VMS, including NK receptor antagonists, with patients using a shared decision-making approach; and Formulate strategies for optimally monitoring patients who are receiving NK receptor antagonists for menopause-related VMS.

Please visit answersincme.com/860/MED-RESP-04317-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Cecelia Damask, DO; Zara M. Patel, MD; Maria Colandrea, DNP, NP-C, CORLN, FAANP; and Dan Shaltanis. In this activity, experts in chronic rhinosinusitis with nasal polyps discuss the latest evidence and practical strategies for optimizing the use of biologic therapies and delivering patient-centered care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the use of biologic therapies to treat patients with chronic rhinosinusitis with nasal polyps (CRSwNP); Differentiate among biologic therapies for patients with CRSwNP based on clinical evidence; and Outline strategies to optimize the holistic management of CRSwNP.